Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $8.24 Consensus Target Price from Brokerages

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $8.24.

ZNTL has been the subject of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. Wells Fargo & Company decreased their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating for the company in a research note on Thursday, January 30th. UBS Group cut their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Finally, Wedbush reaffirmed a "neutral" rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, March 28th.

Insider Transactions at Zentalis Pharmaceuticals

In other news, insider Ingmar Bruns purchased 20,000 shares of the firm's stock in a transaction on Thursday, February 6th. The stock was purchased at an average cost of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares in the company, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Scott Dunseth Myers acquired 21,000 shares of the company's stock in a transaction dated Wednesday, April 30th. The stock was purchased at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the purchase, the director now directly owns 281,192 shares in the company, valued at approximately $393,668.80. This represents a 8.07 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Barclays PLC raised its holdings in shares of Zentalis Pharmaceuticals by 18.5% in the 3rd quarter. Barclays PLC now owns 75,395 shares of the company's stock worth $277,000 after purchasing an additional 11,748 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Zentalis Pharmaceuticals by 115.6% during the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company's stock valued at $171,000 after purchasing an additional 30,240 shares during the last quarter. Savant Capital LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $72,000. Ieq Capital LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth about $46,000. Finally, Anfield Capital Management LLC lifted its stake in Zentalis Pharmaceuticals by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 129,318 shares of the company's stock valued at $392,000 after buying an additional 64,659 shares in the last quarter.

Zentalis Pharmaceuticals Stock Up 3.1 %

Shares of ZNTL stock traded up $0.05 during trading hours on Monday, hitting $1.50. 132,466 shares of the company were exchanged, compared to its average volume of 1,540,130. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $13.24. The firm has a fifty day moving average of $1.59 and a 200 day moving average of $2.46. The firm has a market cap of $107.36 million, a PE ratio of -0.60 and a beta of 1.80.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.09. The firm had revenue of $26.90 million during the quarter. Analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.